Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City
Utah
84108
United States
Tel: 801-584-3600
Fax: 801-584-3640
Website: http://www.myriad.com/
Email: info@myriad.com
About Myriad Genetics, Inc.
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.YEAR FOUNDED:
May 1991
LEADERSHIP:
CEO and Founder: Mark Capone
CMO (Medical): Richard Wenstrup
CFO: Bryan Riggsbee
CSO (Scientific): Jerry Lanchbury
JOBS:
Please click here for Myriad Genetics job opportunities.
CLINICAL TRIAL
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW MYRIAD GENETICS:
Tweets by Myriad Genetics
689 articles about Myriad Genetics, Inc.
-
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
3/21/2024
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.
-
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
3/20/2024
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination.
-
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year;
2/27/2024
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its fourth quarter and full-year ended December 31, 2023 and provided its outlook on business performance for its first quarter and full-year 2024.
-
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
2/27/2024
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a research collaboration with the National Cancer Center Hospital East in Japan to study the prognostic and predictive value of molecular residual disease testing.
-
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2/21/2024
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST.
-
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
2/15/2024
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
-
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
2/1/2024
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.
-
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
1/30/2024
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.
-
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
1/18/2024
Myriad Genetics, Inc. announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.
-
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
1/9/2024
Myriad Genetics, Inc. announced its support for the American Society of Clinical Oncology —Society of Surgical Oncology guideline for germline testing in patients with breast cancer.
-
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST.
-
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
12/21/2023
Myriad Genetics, Inc. today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024.
-
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
12/20/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the launch of the Myriad Collaborative Research Registry™.
-
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
11/20/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test.
-
Myriad Genetics to Participate in Stephens Annual Investment Conference
11/9/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, November 15 at 2:00 p.m. ET.
-
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock - November 09, 2023
11/9/2023
Myriad Genetics, Inc. announced the pricing of an upsized underwritten public offering of 6,470,588 shares of its common stock, par value $0.01 per share, at a public offering price of $17.00 per share for expected gross proceeds of approximately $110 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.
-
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
11/8/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it plans to make a public offering of $100.0 million of shares of its common stock, par value $0.01 per share, in an underwritten registered public offering.
-
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
11/6/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its third quarter ended September 30, 2023.
-
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
11/1/2023
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.
-
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
10/31/2023
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT.